Ala Eddin Sagar/LinkedIn
Mar 22, 2026, 16:21
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center – Madinah, shared a post on LinkedIn:
Apixaban or rivaroxaban for acute VTE?
This study is one of three papers discussed in this week’s episode of This Week in Pulmonary and Critical Care Medicine.
We review:
- A randomized trial comparing apixaban vs rivaroxaban for VTE
- An ICU study on oscillatory airway therapy in ventilated patients
- A teaching discussion on how mitral valve disease affects the lungs
Curious how others are interpreting the DOAC trial.
Do you favor apixaban or rivaroxaban for acute VTE?
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026